Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

Gain valuable insights into novel therapies, ongoing clinical trials, and future innovations shaping the treatment of ...

At least one-third of the world's population has been infected with the hepatitis B virus (HBV), and 400 million people are chronic carriers. In most populations, chronic HBV infection is the ...

The company is dedicated to educating patients, providers, and others on new findings in chronic hepatitis B virus (HBV ... and molecules targeting the viral capsid, which results in inhibition ...

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the ...